Artificial Intelligence in Thoracic Radiation Oncology: Patient Evaluation and Treatment Planning
Grace Lee, MD+more
In part 1 of a 2-part article, Grace Lee, MD, Fridolin Haugg, MSc, and Raymond H. Mak, MD, explore the possibilities and limitations of AI applications. Read more
In an interview with ILCN, Drs. Puneeth Iyengar and Matthias Guckenberger said despite a lack of phase III data in this space, science-based recommendations are needed to optimize multimodal therapy. Read more
New Registry Aims to Expand Knowledge of Lung Cancer Treatment During Pregnancy
Erin JungmeyerDr. Narjust Florez, who is spearheading the effort at Dana Farber, says the need for research on cancer therapies for pregnant patients is urgent as both maternal age and the number of young lung cancer diagnoses are increasing. Read more
Screening Experts Outline Considerations for LDCT Screening Programs
Erin JungmeyerLead author Dr. Claudia Henschke says a recently published perspective from the IASLC Early Detection and Screening Committee explores several components of effective screening efforts, including timing between screenings. Read more
Combining SABR with Immunotherapy to Improve Outcomes in Early-Stage NSCLC
Famke L. Schneiders, MD, PhD+more
Drs. Famke L. Schneiders and Suresh Senan explore evidence that supports the use of radiotherapy to prime the immune system to maximize the benefits of immunotherapy. Read more
Patterns of Failure after PACIFIC: How to Address Disease Recurrence after Chemoradiotherapy and Immunotherapy
Cole M. Friedes, MD+more
Dr. Cole M. Friedes and colleagues analyzed progression patterns in patients after receiving the PACIFIC regimen and showed that many patients are candidates for further ablative treatments. Read more
Research Supports Use of Lung Nodule Programs to Improve Early Detection Efforts
Erin JungmeyerA study by Dr. Raymond U. Osarogiagbon and colleagues found that such programs may benefit patients deemed too young or too old for lung cancer screening based on existing guidelines. Read more
US FDA Announces Multiple Moves with Implications for Lung Cancer Care
Erin JungmeyerAt the end of 2023, the agency approved repotrectinib for ROS1+ NSCLC, granted priority review for tarlatamab for advanced SCLC, and asked for an additional confirmatory trial for sotorasib for KRAS G12C-mutated NSCLC. Read more
As the IASLC celebrates its 50th year, the association’s journal moves to online only and the American Cancer Society recommends expanding screening eligibility. Read more